Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3537-3543

  Motohashi, Noboru ^a   Kurihara, Teruo ^b   Kawase, Masami ^b   Hevér, Anikó ^c   Tanaka, Masaru ^c   Szabo, Diana ^c   Nacsa, János ^c   Yamanaka, Wataru ^b   Kerim, Ablikim ^d   Molnár, Joseph ^c  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c UNIVERSITY OF SZEGED   (Hungary)

^d XINJIANG UNIVERSITY   (China)

Author keywords

Anti mutagenicity; Bacteria antiplasmid; Mutagenicity; Reversal of multidrug resistance; Reverse transcriptase inhibition; Ring substituted chlorpromazines; Synergism; Tumor cells

Indexed keywords

ANTIMUTAGENIC AGENT; ANTIRETROVIRUS AGENT; GLYCOPROTEIN P; HEMOLYSIN; PHENOTHIAZINE DERIVATIVE; PHTHALIMIDE DERIVATIVE; RHODAMINE 123; RNA DIRECTED DNA POLYMERASE; TETRACYCLINE; VERAPAMIL;

AMES TEST; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ESCHERICHIA COLI; FLOW CYTOMETRY; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; MULTIDRUG RESISTANCE; MUTAGENICITY; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM;

ANTIMUTAGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CHEMISTRY, PHYSICAL; DRUG RESISTANCE, MULTIPLE; ESCHERICHIA COLI; MOLECULAR STRUCTURE; MOLONEY MURINE LEUKEMIA VIRUS; MUTAGENS; PHENOTHIAZINES; PLASMIDS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRACYCLINE;

EID: 0030774088     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. (a) Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchars KL and Victor L: Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324: 485-489, 1986.
2. (b) Bradley G and Juranka PF, Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
3. (c) Gottesman MM and Pastan I: Biochemistry of multidrug mediated by the multidrug transporter. Ann Rev Biochem 62: 385-427, 1993.
4. Motohashi N, Kawase M, Kurihara T, Hevér A, Nagy Sz, Ocsovszki I, Tanaka M and Molnár J: Synthesis and antitumor activity of 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas as potent anticancer agents. Anticancer Res 16: 2525-2531, 1996.
5. Fleckenstein A: Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol 17: 149-166, 1977.
6. Janis RA, Silver PJ and Triggle DJ: Drug action and cellular calcium regulation. Adv Drug Res 16: 309-591, 1987.
7. Alföldi L, Rasko I and Kerekes E: L-Serine deaminase of E. coli. J Bacteriol 86: 1512-1518, 1968.
8. Molnár J, Kiraly J and Mándi Y: Antibacterial action and R-factor inhiting activity of chlorpromazine. Experientia 31: 444-445, 1975.
9. Mándi Y, Molnár J, Holland IB and Béládi I: Efficient curing of an Escherichia coli F-prime plasmid by phenothiazines. Genet Res Commun 26: 109-111, 1976.
10. Lederberg J and Lederberg EM: Replica plating and indirect selection of bacterial mutants. J Bacteriology 63: 399-406, 1952.
11. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486-4490, 1988.
12. Weaver JL, Szabo G, Pine PS, Gottesman MM, Goldenberg S and Aszalos A: The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer 54: 456-461, 1993.
13. Kessel D: Exploring multidrug resistance using rhodamine 123. Cancer Commun 1: 145-149, 1989.
14. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J and Rosenberg SA: Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 54: 1766-1771, 1994.
15. Maron DM and Ames BN: Revised methods for the Salmonella mutagenicity test. Mutation Res 113: 173-215, 1983.
16. (a) MOPAC ver. 6.00, J.J.P. Stewart, QCPE Bull 9: 10, 1989. (b) Revised as ver. 6.01 by Yoshihisa Inoue, JCPE Newslett 4: 60, 1992.
17. (a) MOPAC ver. 6.00, J.J.P. Stewart, QCPE Bull 9: 10, 1989. (b) Revised as ver. 6.01 by Yoshihisa Inoue, JCPE Newslett 4: 60, 1992.
18. Rohrer DC: 3D molecular similarity modelling in computational drug design. In: Molecular Similarity and Reactivity. From Quantum Chemical to Phenomenological Approaches. (Carbó R ed). Understanding Chemical Reactivity vol.14. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1995, pp141-161.
19. Molnár J, Mándi Y, Boda K and Földeák S: The effect of ring-substituted and quaternary chlorpromazine derivatives on the survival of the NK/Ly ascites tumor bearing mice. Neoplasma 29: 215-222. 1982.
20. Motohashi N: Test for Antitumor activities of phenothiazines and phenoxazines (in Japanese). Yakugaku Zasshi 103: 364-371, 1983.
21. Molnár J, Taródi B, Gálfi M, Matkovics B and Motohashi N: In vitro antiproliferative effects of tricyclic psychopharmacons and synergism with some resistance modifiers. Anticancer Res 12: 273-280, 1992.
22. Mucsi I, Molnár J, Burián K, Béládi I, Sakagami H, Nakashima H, Inazawa K and Motohashi N: Antiviral activity of phenothiazine and benzo[a]phenothiazine derivatives. In: Biological and Chemical Aspects of Thiazines and Analogs, eds Jacques Barbe, H. Keyzer and Jean Claude Soyfer, Enlight Associates. pp 347-356, 1995.
23. Molnár J, Pusztai R, Hevér A, Nagy Sz and Motohashi N: Effects of two benzo[a]phenothiazines on multi-drug resistance (mdr) and tumor antigen expression. Anticancer Res 15: 2013-2016, 1995.